A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

ClinicalTrials.gov processed this data on November 15, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

RECRUITING (See Contacts and Locations)
Verified November 2024 by Hoffmann-La Roche, Chugai Pharmaceutical

Sponsor

Hoffmann-La Roche

Information Provided by (Responsible Party)

Hoffmann-La Roche

Clinicaltrials.gov Identifier

NCT05904886
Other Study ID Numbers: CO44668
First Submitted: May 23, 2023
First Posted: June 15, 2023
Last Update Posted: November 18, 2024
Last Verified: November 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Carcinoma, Hepatocellular
  • Drug: Atezolizumab
  • Drug: Bevacizumab
  • Drug: Tiragolumab
  • Other: Placebo

Study Design

Study TypeInterventional
Anticipated Enrollment650 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingQuadruple
Primary PurposeTreatment
Official TitleA Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Study Start DateSeptember 14, 2023
Anticipated Primary Completion DateSeptember 1, 2026
Anticipated Study Completion DateSeptember 1, 2026

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Atezolizumab + Bevacizumab + Tiragolumab
    • Atezolizumab plus bevacizumab plus tiragolumab will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
  • Drug: Atezolizumab
    • Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
  • Drug: Bevacizumab
    • Drug: Tiragolumab
      • Atezolizumab + Bevacizumab + Placebo
        • Atezolizumab, bevacizumab plus placebo will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
      • Drug: Atezolizumab
        • Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
      • Drug: Bevacizumab
        • Other: Placebo

          Outcome Measures

          Primary Outcome Measures

          1. Investigator-Assessed Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)]
          2. Overall Survival (OS) [From randomization to death from any cause (up to approximately 36 months)]

          Secondary Outcome Measures

          1. Investigator-Assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 [From randomization up to approximately 36 months]
          2. Investigator-Assessed Duration of Objective Response (DOR) According to RECIST v1.1 [From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)]
          3. Investigator-Assessed PFS Rate According to RECIST v1.1 at 6 and 12 Months [Month 6, Month 12]
          4. OS Rate at 1 and 2 Years [Year 1, Year 2]
          5. Investigator-Assessed PFS According to Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) [From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)]
          6. Investigator-Assessed Confirmed ORR According to HCC mRECIST [From randomization up to approximately 36 months]
          7. Investigator-Assessed DOR According to HCC mRECIST [From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)]
          8. Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer 30 (QLQ-C30) Subscales [From randomization up to approximately 36 months]
            The following subscales of the EORTC QLQ-C30 will be used for the assessment: global health status/quality-of-life (GHS/QoL), physical functioning and role functioning. GHS and QoL are scored on a 7-point scale: 1=Very poor to 7=Excellent. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with a higher score indicating a worse outcome. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. A higher score indicates a better outcome.
          9. Change from Baseline in GHS/QoL, Physical Functioning, and Role Functioning Assessed Using the EORTC QLQ-C30 [From baseline up to approximately 36 months]
            GHS and QoL are scored on a 7-point scale: 1=Very poor to 7=Excellent. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with a higher score indicating a worse outcome. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. A higher score indicates a better outcome.
          10. Percentage of Participants With Adverse Events [Up to approximately 36 months]
          11. Serum Concentrations of Atezolizumab [Prior to the first infusion and 30 minutes after atezolizumab infusion on Day 1 of Cycle 1 (cycle = 21 days), prior to infusion on Day 1 of Cycles 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)]
          12. Serum Concentrations of Tiragolumab [Prior to the first infusion and 30 minutes after tiragolumab infusion on Day 1 of Cycle 1 (cycle = 21 days), prior to infusion on Day 1 of Cycles 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)]
          13. Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab [Prior to the first infusion on Day 1 of Cycles (cycle = 21 days) 1, 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)]
          14. Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab [Prior to the first infusion on Day 1 of Cycles (cycle = 21 days) 1, 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)]

          Eligibility Criteria

          Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
          Sexes Eligible for Study All
          Accepts Healthy Volunteers No
          Inclusion Criteria
          • Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
          • Disease that is not amenable to curative surgical and/or locoregional therapies
          • No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC
          • Measurable disease according to RECIST v1.1
          • ECOG Performance Status of 0 or 1 within 7 days prior to randomization
          • Child-Pugh Class A within 7 days prior to randomization
          • Adequate hematologic and end-organ function
          • Female participants of childbearing potential must be willing to avoid pregnancy within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo
          • Male participants with a female partner of childbearing potential or pregnant female partner must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of bevacizumab and for 90 days after the final dose of tiragolumab/placebo to avoid exposing the embryo.
          Exclusion Criteria
          • Pregnancy or breastfeeding within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo
          • Prior treatment with CD137 agonists or immune checkpoint blockade therapies
          • Treatment with investigational therapy within 28 days prior to initiation of study treatment
          • Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
          • Treatment with systemic immunostimulatory agents
          • Treatment with systemic immunosuppressive medication
          • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
          • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
          • Active or history of autoimmune disease or immune deficiency
          • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
          • History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
          • Mixed histology or other subtypes/variants of HCC, including, but not limited to, known liver adenocarcinoma, fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
          • Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
          • Acute Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection
          • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

          Contacts and Locations

          Sponsors and Collaborators Hoffmann-La Roche, Chugai Pharmaceutical
          Chugai Pharmaceutical
          Locations
          • Genesis Cancer Center | Hot Springs, Arkansas, United States, 71913
          • UCLA MEDICAL CENTER; Alhambra | Alhambra, California, United States, 91801
          • UCSF Fresno at Community Cancer Institute | Clovis, California, United States, 93611
          • City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics | Duarte, California, United States, 91010
          • University of California San Diego Moores Cancer Center | La Jolla, California, United States, 92037
          • Kaiser Permanente - Los Angeles (N. Vermont) | Los Angeles, California, United States, 90027
          • University of Southern California | Los Angeles, California, United States, 90033
          • USC Norris Cancer Center; Oncology/Hematology - Newport Beach Treatment Center | Newport Beach, California, United States, 92663
          • Kaiser Permanente - Oakland | Oakland, California, United States, 94611
          • Stanford Cancer Center | Palo Alto, California, United States, 94304
          • Va Palo Alto Health Care System | Palo Alto, California, United States, 94304
          • Kaiser Permanente - Roseville | Roseville, California, United States, 95661
          • Kaiser Permanente - San Francisco (2238 Geary) | San Francisco, California, United States, 94115
          • Kaiser Permanente - Santa Clara; Oncology Clinical trials | Santa Clara, California, United States, 95051
          • UCLA Cancer Center | Santa Monica, California, United States, 90404
          • Kaiser Permanente; Oncology Clinical Trials | Vallejo, California, United States, 94589
          • Kaiser Permanente - Walnut Creek | Walnut Creek, California, United States, 94596
          • Rocky Mountain Cancer Center | Denver, Colorado, United States, 80218
          • Hartford Healthcare Cancer Institute at Hartford Hospital | Hartford, Connecticut, United States, 06106
          • MedStar Washington Hosp Center | Washington, District of Columbia, United States, 20010
          • Florida Cancer Specialists - Fort Myers (Broadway) | Fort Myers, Florida, United States, 33901
          • Mayo Clinic Cancer Center | Jacksonville, Florida, United States, 32224
          • Miami VA Healthcare System | Miami, Florida, United States, 33125
          • AdventHealth Cancer Institute | Orlando, Florida, United States, 32804
          • Florida Cancer Specialist, North Region | Saint Petersburg, Florida, United States, 33705
          • Grady Health System | Atlanta, Georgia, United States, 30303
          • Winship Cancer Institute of Emory University | Atlanta, Georgia, United States, 30329
          • University of Illinois | Chicago, Illinois, United States, 60612
          • Capt. James A. Lovell Federal Health Care Center | North Chicago, Illinois, United States, 60064
          • Norton Cancer Institute - Audubon | Louisville, Kentucky, United States, 40217
          • Hematology Oncology Clinic | Baton Rouge, Louisiana, United States, 70809
          • Ochsner Cancer Inst. | New Orleans, Louisiana, United States, 70121
          • Mercy Medical Center | Baltimore, Maryland, United States, 21202
          • VA Medical Center - Ann Arbor | Ann Arbor, Michigan, United States, 48105
          • Henry Ford Health System | Detroit, Michigan, United States, 48202
          • Cancer & Hematology Centers of Western Michigan | Grand Rapids, Michigan, United States, 49503
          • G.V. (Sonny) Montgomery VA Medical Center | Jackson, Michigan, United States, 39216
          • Mayo Clinic Rochester; Medical Oncology | Rochester, Minnesota, United States, 55905
          • Minnesota Oncology Hematology Woodbury | Woodbury, Minnesota, United States, 55125
          • Washington Uni School of Medicine | Saint Louis, Missouri, United States, 63110
          • Renown Regional Medical Center | Reno, Nevada, United States, 89502
          • Montefiore Medical Center | Bronx, New York, United States, 10461
          • James J Peters VA Hospital / Mental Illness Research Education and Clinic Center | Bronx, New York, United States, 10468
          • NYU Langone | New York, New York, United States, 10003
          • Icahn School of Medicine at Mount Sinai | New York, New York, United States, 10029
          • Columbia University | New York, New York, United States, 10032-3725
          • University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States, 27514
          • University of Cincinnati | Cincinnati, Ohio, United States, 45203-0542
          • Univ Hospitals of Cleveland | Cleveland, Ohio, United States, 44106
          • OU Health Stephenson Cancer Center | Oklahoma City, Oklahoma, United States, 73104
          • Thomas Jefferson Uni | Philadelphia, Pennsylvania, United States, 19107
          • VA Pittsburgh Healthcare System | Pittsburgh, Pennsylvania, United States, 15240
          • Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins | Willow Grove, Pennsylvania, United States, 19090
          • Texas Oncology - Austin | Austin, Texas, United States, 78745
          • North Texas VA Medical Center | Dallas, Texas, United States, 75216
          • Texas Oncology - DFW | Dallas, Texas, United States, 75246
          • Kelsey Seybold Clnic | Houston, Texas, United States, 77025
          • Houston Methodist Cancer Center | Houston, Texas, United States, 77030
          • Michael E Debakey VA Medical Center | Houston, Texas, United States, 77030
          • Texas Oncology - Northeast Texas | Tyler, Texas, United States, 75702
          • Virginia Cancer Specialists - Arlington | Arlington, Virginia, United States, 22205
          • Virginia Commonwealth Uni Health Center | Richmond, Virginia, United States, 23298
          • Swedish Cancer Institute - Edmonds Campus | Edmonds, Washington, United States, 98026
          • Swedish Cancer Institute - Issaquah | Issaquah, Washington, United States, 98029
          • Virginia Mason Medical Center | Seattle, Washington, United States, 98101
          • Swedish Cancer Inst. | Seattle, Washington, United States, 98104
          • Univ of Wisconsin-Madison | Madison, Wisconsin, United States, 53705
          • William S Middleton Memorial Veterans Hospital (CARES); Research ATTN: Pharmacy 119 | Madison, Wisconsin, United States, 53705
          • Imeldaziekenhuis | Bonheiden, Belgium, 2820
          • Hospital Erasme | Bruxelles, Belgium, 1070
          • Cliniques Universitaires St-Luc | Bruxelles, Belgium, 1200
          • UZ Antwerpen | Edegem, Belgium, 2650
          • UZ Leuven Gasthuisberg | Leuven, Belgium, 3000
          • AZ Delta (Campus Rumbeke) | Roeselare, Belgium, 8800
          • CEDOES - Diagnóstico e Pesquisa | Vitoria, ES, Brazil, 29055-450
          • Oncoclínicas do Brasil - BELO HORIZONTE | Belo Horizonte, MG, Brazil, 30170-080
          • Hospital do Cancer de Pernambuco - HCP | Recife, PE, Brazil, 50040-000
          • Clinicas Oncologicas Integradas - COI | Rio De Janeiro, RJ, Brazil, 22290-160
          • Hospital de Amor Amazônia | Porto Velho, RO, Brazil, 76834-899
          • Santa Casa de Misericordia de Porto Alegre | Porto Alegre, RS, Brazil, 90020-090
          • Hospital Sao Lucas - PUCRS | Porto Alegre, RS, Brazil, 90610-000
          • Hospital de Cancer de Barretos | Barretos, SP, Brazil, 14784-400
          • Instituto do Cancer do Estado de Sao Paulo - ICESP | Sao Paulo, SP, Brazil, 01246-000
          • Hospital A. C. Camargo; Oncologia | Sao Paulo, SP, Brazil, 01509-010
          • Centro Paulista de Oncologia | Sao Paulo, SP, Brazil, 04538-132
          • Cross Cancer Institute | Edmonton, Alberta, Canada, T6G 1Z2
          • William Osler Health Centre | Etobicoke, Ontario, Canada, M9V 1R8
          • Juravinski Hospital | Hamilton, Ontario, Canada, L8V 1C3
          • Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada, M4N 3M5
          • Jewish General Hospital | Montreal, Quebec, Canada, H3T 1E2
          • McGill University Health Centre - Glen Site | Montreal, Quebec, Canada, H4A 3J1
          • Baoji Central Hospital | Baoji City, China, 721008
          • Beijing Youan Hospital, Capital Medical University; Center for Infectious Diseases | Beijing City, China, 100069
          • Beijing Cancer Hospital | Beijing, China, 100142
          • The First Hospital of Jilin University | Changchun City, China, 130021
          • Hunan Cancer Hospital | Changsha CITY, China, 410013
          • Peoples Hospital of Hunan Province | Changsha, China, 410007
          • West China Hospital - Sichuan University | Chengdu City, China, 610047
          • The First Affliated Hospital Of Fujian Medical University; Intervention Department | Fuzhou City, China, 350005
          • Mengchao Hepatobiliary Hospital Of Fujian Medical University | Fuzhou City, China, 350025
          • The First Affiliated Hospital of Sun Yat-sen University | Guangzhou City, China, 510080
          • Nanfang Hospital, Southern Medical University | Guangzhou, China, 510515
          • Sun yat-sen University Cancer Center; Department of Liver Surgery | Guangzhou, China,
          • The First Affiliated Hospital of College of Medicine, Zhejiang University | Hangzhou, China, 310003
          • Zhejiang Provincial People?s Hospital | Hangzhou, China, 310014
          • Harbin Medical University Cancer Hospital | Harbin, China, 150081
          • Anhui Provincial Hospital | Hefei, China, 230001
          • The Second Affiliated Hospital of Anhui Medical University | Hefei, China,
          • Shandong Cancer Hospital | Jinan, China, 250117
          • Lishui Central Hospital | Lishui City, China, 323000
          • Guangxi Cancer Hospital of Guangxi Medical University | Nanning City, China, 530021
          • The First Affiliate Hospital of Guangxi Medical University | Nanning, China, 530021
          • Zhongshan Hospital Fudan Unvierstiy | Shanghai City, China, 200032
          • Renji Hospital Shanghai Jiaotong University School of Medicine | Shanghai City, China, 200127
          • Shengjing Hospital of China Medical University | ShenYang, China, 110004
          • Tianjin Cancer Hospital | Tianjin, China, 300060
          • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan City, China, 430030
          • First Affiliated Hospital of Medical College of Xi'an Jiaotong University | Xi'an, China, 710061
          • Xi'an Inernational Medical Center Hospital | Xi'an, China, 710119
          • Polyclinique Internationale Sainte Anne- Marie (PISAM) | Abidjan, Côte D'Ivoire, BP 1463 Abidjan
          • Centre National d'Oncologie Médicale et de Radiothérapie Alassane Ouattara (CNRAO) | Abidjan, Côte D'Ivoire,
          • CHU CAEN - Hôpital de la Côte de Nacre; Service Hepatogastroenterologie | Caen Cedex, France, 14033
          • Hôpital Albert Michallon | La Tronche, France, 38700
          • CHRU de Lille - Hopital Claude Huriez | Lille, France, 59037
          • Hopital Dupuytren; Hepatologie Gastro Enterologie | Limoges, France, 87042
          • Fondation Hopital Saint Joseph; Gastro-Enterologie | Marseille, France, 13285
          • CH Saint Eloi | Montpellier, France, 34295
          • Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie | Nantes, France, 44093
          • APHP - Hopital Saint Antoine | Paris, France, 75571
          • Hopital Robert Debre; Gastro Enterologie | Reims, France, 51092
          • Centre Hospitalier Valence | Valence, France, 26953
          • Hopitaux de Brabois - Gastro-Entereologie | Vandoeuvre-les-nancy, France, 54511
          • Hopital Paul Brousse; Centre Hepatologie Biliaire | Villejuif, France, 94804
          • Klinikum Esslingen; Allg. Innere Med., Onkologie, Hämatologie, Gastroenterologie und Infektiologie | Esslingen, Germany, 73730
          • Klinik für Gastroenterologie und Gastrointestinale Onkologie der UMG | Göttingen, Germany, 37075
          • Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Medizinische Klinik I | Lübeck, Germany, 23562
          • Universitätsklinikum Magdeburg Klinik für Gastroenterologie und Hepatologie | Mageburg, Germany, 39120
          • Uniklinik Mainz; I. Medizinische Klinik | Mainz, Germany, 55131
          • Universität Tübingen; Med. Klinik; Innere Medizin I | Tübingen, Germany, 72076
          • Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I | Ulm, Germany, 89081
          • Queen Mary Hospital; Dept. Of Haematology & Oncology | Hong Kong, Hong Kong,
          • Prince of Wales Hosp; Dept. Of Clinical Onc | Shatin, Hong Kong,
          • Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica | Napoli, Campania, Italy, 80131
          • A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi) | Bologna, Emilia-Romagna, Italy, 40138
          • Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome, Lazio, Italy, 00168
          • Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical | Genova, Liguria, Italy, 16132
          • IRCCS Istituto Clinico Humanitas; Oncologia | Rozzano (MI), Lombardia, Italy, 20089
          • Az. Osp. G. Panico; U.O. Oncologia | Tricase (LE), Puglia, Italy, 73039
          • A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed Epatologia | Palermo, Sicilia, Italy, 90100
          • A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U. | Verona, Veneto, Italy, 37134
          • Fujita Health University Hospital | Aichi, Japan, 470-1192
          • Chiba University Hospital | Chiba, Japan, 260-8677
          • National Cancer Center Hospital East | Chiba, Japan, 277-8577
          • Ehime Prefectural Central Hospital | Ehime, Japan, 790-0024
          • Kurume University Hospital | Fukuoka, Japan, 830-0011
          • Hiroshima University Hospital | Hiroshima, Japan, 734-8551
          • Sapporo Kosei Genaral Hospital | Hokkaido, Japan, 060-0033
          • Hokkaido University Hospital | Hokkaido, Japan, 060-8648
          • Japanese Red Cross Society Himeji Hospital | Hyogo, Japan, 670-8540
          • Kanazawa University Hospital | Ishikawa, Japan, 920-8641
          • Iwate Medical University Hospital | Iwate, Japan, 028-3695
          • Toranomon Branch Hospital | Kanagawa, Japan, 213-8587
          • Kanagawa Cancer Center | Kanagawa, Japan, 241-8515
          • Kitasato University Hospital | Kanagawa, Japan, 252-0375
          • University Hospital Kyoto Prefectural University of Medicine | Kyoto, Japan, 602-8566
          • Kyoto University Hospital | Kyoto, Japan, 606-8507
          • Osaka University Hospital | Osaka, Japan, 565-0871
          • Kindai University Hospital | Osaka, Japan, 589-8511
          • Jichi Medical University Hospital | Tochigi, Japan, 329-0498
          • Toranomon Hospital | Tokyo, Japan, 105-8470
          • Japanese Red Cross Musashino Hospital | Tokyo, Japan, 180-8610
          • University of Nairobi - Institute of Tropical and Infectious Diseases | Nairobi, Kenya, 19676-00202
          • National Cancer Center | Goyang-si, Korea, Republic of, 10408
          • CHA Bundang Medical Center | Gyeonggi-do, Korea, Republic of, 13496
          • Chonnam National University Hwasun Hospital | Jeollanam-do, Korea, Republic of, 58128
          • Seoul National University Hospital | Seoul, Korea, Republic of, 03080
          • Severance Hospital, Yonsei University Health System | Seoul, Korea, Republic of, 03722
          • Asan Medical Center | Seoul, Korea, Republic of, 05505
          • Samsung Medical Center | Seoul, Korea, Republic of, 06351
          • Ulsan University Hosiptal | Ulsan, Korea, Republic of, 44033
          • OncoMed; Supportive Care | Ciudad de México, Mexico CITY (federal District), Mexico, 03100
          • Centro Medico Nacional Siglo Xxi - Imss; Hospital de Oncologia | Mexico City, Mexico CITY (federal District), Mexico, 06720
          • Instituto Nacional de Ciencias Médicas Y de Nutricion Salvador Zubirán | Mexico DF, Mexico CITY (federal District), Mexico, 14000
          • Oncare | San Pedro Garza García, Nuevo LEON, Mexico, 66220
          • Centro de Investigacion Clinica de Oaxaca | Oaxaca de Juárez, Oaxaca, Mexico, 68020
          • CHU Ibn Rochd _ Centre Mohammed VI pour le traitement des cancers; Oncology | Casablanca, Morocco, 20502
          • Centre Hospitalier Universitaire Hassan II | FES, Morocco, 30000
          • Centre Hospitalier Universitaire Mohamed VI; Oncologie-Hématologie | Marrakech, Morocco, 40000
          • Institut National D'oncologie Sidi Med Benabdellah | Rabat, Morocco, 6213
          • Auckland City Hospital | Auckland, New Zealand, 1023
          • Christchurch Hospital; Gastroenterology Dept | Christchurch, New Zealand, 8011
          • Wellington Hospital | Wellington, New Zealand, 6021
          • Jos University Teaching Hospital; Internal medicine and Gastroenterology | JOS, Nigeria, 930232
          • Lagos University Teaching Hospital Lagos (LUTH), Lagos State | Lagos, Nigeria,
          • Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii; Oddzia? Onkologii Klinicznej | Gdansk, Poland, 80-219
          • Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii | Kraków, Poland, 30-688
          • ID Clinic | Myslowice, Poland, 41-400
          • NIO im Marii Sklodowskiej-Curie; Klinika Onkologii i Radioterapii | Warszawa, Poland, 02-034
          • PanOncology Trials; Hospital Oncológico, Puerto Rico Medical Center | San Juan, Puerto Rico, 00935
          • National University Hospital; National University Cancer Institute, Singapore (NCIS) | Singapore, Singapore, 119228
          • National Cancer Centre; Medical Oncology | Singapore, Singapore, 168583
          • Tan Tock Seng Hospital; Oncology | Singapore, Singapore, 308433
          • Curie Oncology | Singapore, Singapore, 329563
          • Charlotte Maxeke Johannesburg Academic Hospital | Johannesburg, South Africa, 2193
          • Limpopo Cancer Research Institute | Polokwane, South Africa, 0700
          • University of Pretoria; Department of Medical Oncology | Pretoria, South Africa, 0002
          • Hospital Universitario Central de Asturias; Servicio de Hepatología | Oviedo, Asturias, Spain, 33011
          • Clinica Universitaria de Navarra; Servicio de Hepatologia | Pamplona/iruña, Navarra, Spain, 31008
          • Hospital Universitari Vall d'Hebron; Servicio de Hepatologia | Barcelona, Spain, 08035
          • Hospital Clinic i Provincial; Servicio de Hepatología | Barcelona, Spain, 08036
          • Hospital Duran i Reynals; Oncologia | Barcelona, Spain, 08907
          • Hospital Universitario de Burgos; Oncología | Burgos, Spain, 09006
          • Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia | Jaen, Spain, 23007
          • Hospital General Universitario Gregorio Marañon; Servicio de Aparato Digestivo | Madrid, Spain, 28007
          • Clinica Universitaria de Navarra de Madrid; Servicio de Hepatologia; Servicio de Hepatologia | Madrid, Spain, 28027
          • Hospital Clinico San Carlos; Servicio de Oncologia | Madrid, Spain, 28040
          • Hospital Universitario Puerta de Hierro; Servicio de Gastroenterologia | Madrid, Spain, 28222
          • Hospital de Navarra; Servicio de Oncologia | Navarra, Spain, 31008
          • Hospital Clinico de Valencia; Servicio de Hepatologia | Valencia, Spain, 46010
          • China Medical University Hospital; Surgery | Taichung, Taiwan, 404
          • National Cheng Kung University Hospital; Oncology | Tainan, Taiwan, 00704
          • Chi-Mei Medical Centre; Hematology & Oncology | Tainan, Taiwan, 710
          • National Taiwan Uni Hospital; Dept of Oncology | Taipei, Taiwan, 100
          • Chang Gung Medical Foundation - Linkou; Dept. of Hepato-Gastroenterology | Taoyuan, Taiwan, 333
          • Chulalongkorn Hospital; Medical Oncology | Bangkok, Thailand, 10330
          • Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc | Bangkok, Thailand, 10400
          • Maharaj Nakorn Chiang Mai Hospital; Department of Medicine | ChiangMai, Thailand, 50200
          • Khon Kaen Uni ; Faculty of Medicine, Division of Gastroenterology | Khon Kaen, Thailand, 40002
          • Adana Baskent University Medical Faculty; Oncology | Adana, Turkey, 01220
          • Ankara Bilkent City Hospital | Ankara, Turkey, 06490
          • Gazi Uni Medical Faculty Hospital; Oncology Dept | Ankara, Turkey, 06500
          • Dicle University Faculty of Medicine | Diyarbakir, Turkey, 21280
          • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi | Edirne, Turkey, 22030
          • ?zmir Medical Point; Oncology | Kar?iyaka, Turkey, 35575
          • Western General Hospital; Dept of Oncology | Edinburgh, United Kingdom, EH4 2XU
          • Royal Free Hospital; Dept of Oncology | London, United Kingdom, NW3 2QG
          • Hammersmith Hospital; Clinical trials unit | London, United Kingdom, W12 0HS
          Investigators

            More Information

            Additional Relevant MeSH Terms

            • Carcinoma
            • Carcinoma, Hepatocellular
            • Neoplasms, Glandular and Epithelial
            • Neoplasms by Histologic Type
            • Neoplasms
            • Adenocarcinoma
            • Liver Neoplasms
            • Digestive System Neoplasms
            • Neoplasms by Site
            • Digestive System Diseases
            • Liver Diseases